Dr. Johnson of the University of Utah received consulting fees from AMO Pharma, University of Utah, and AveXis and a research grant from Biogen Idec.)
Ms. Stock of the American Academy of Neurology has no relevant financial relationships to disclose.)
Ms. Kaloides of the American Academy of Neurology has no relevant financial relationships to disclose.)
Dr. Ciafaloni of the University of Rochester received consulting fees from Biogen and Pfeizer and research grants from Sarepta and Santhera.)
This article includes discussion of the high cost of new treatments for neuromuscular diseases and the Orphan Drug Act.
Neuromuscular diseases are on the forefront of therapeutic development. Three new disease-modifying therapies have been approved in the past 12 months for rare neuromuscular disorders, an unprecedented pace for any area of neurology. The favorable regulatory landscape for orphan disease has provided the impetus to invest in these disorders. However, the cost and intensity of these therapies have provided new challenges to physicians treating these debilitating illnesses. In this article, the authors describe the challenges and identify some solutions moving forward.
• Incentives within the Orphan Drug Act have promoted research in rare neuromuscular diseases.
• New disease-modifying therapies in neuromuscular disease are difficult to implement given the cost and route of administration.
• Initial implementation in multidisciplinary clinics may be the most feasible approach.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.